title: Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review.
abstract: Intravenous immunoglobulins (IVIGs) are generally used as replacement therapy for humoral immunodeficiencies. In consideration of their immune-modulating properties, they are also employed as "immune-modulating/anti-inflammatory" treatment in different clinical conditions. In HIV-1 infection, an increased incidence of autoimmune and auto-inflammatory manifestations has been described, probably as a consequence of the chronic immune activation associated with the disease. The initial use in the treatment of bacterial infections in children with HIV/AIDS has been replaced by the treatment, in combination with antiretroviral therapy, of these autoimmune/inflammatory conditions. We review the results obtained with IVIGs therapy in these HIV-1-associated clinical manifestations.
authors.affiliation: Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Pastori
authors.forename: Antonella
authors.initials: A
authors.lastname: Esposito
authors.forename: Ivano
authors.initials: I
authors.lastname: Mezzaroma
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology / Q000821:virology; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002648:Child; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors